StockMacro
Company, fund or insider

Help

Menu

Eric Mark Green

Insider (Form 4 reporting owner): Director CIK 1336007Name as filed: Green Eric MarkIts filings on EDGARAll insiders

Measures activity, not value. Not investment advice.

Since 5 Dec 2022, sold $114.7M in 7 sales (3 under a 10b5-1 plan set in advance) and bought $1.0M in 1 open-market purchase across 2 companies.

Companies

Role on the latest Form 4 for each; open-market trades counted
CompanyRoleTrades fromtoPurchasesSales
West Pharmaceutical Services WSTPresident, CEO and Board Chair5 Dec 20226 Aug 2024–7$114.7M
Ecolab ECLDirector11 Sep 202611 Sep 20261$1.0M–

What the share price did after their trades Share price return after each open-market trade, from the first close after the Form 4 became public, minus the return of the company's sector fund (the S&P 500 fund when the sector has none) over the same days. Median over the trades, in percentage points; at most one trade per company, side and month. It describes the past.

Median return minus the sector fund, in percentage points; "too few trades" under 5
Open-market tradesAfter 3 monthsAfter 6 monthsAfter 12 months
After purchasesno trade old enoughno trade old enoughno trade old enough
After sales+8.1 pts7 trades, 57% above the sector-2.2 pts7 trades, 43% above the sector-9.0 pts7 trades, 14% above the sector

For a sale, a negative number means the shares did worse than the sector afterwards. It describes the past, not what comes next.

By year

Counted open-market trades, by trade date
YearPurchasesBoughtSalesSoldNet
20261$1.0M––$1.0M
2024––3$56.6M-$56.6M
2023––3$47.5M-$47.5M
2022––1$10.5M-$10.5M

Every trade

9, newest first; open-market purchases and sales only
Trade dateCompanySideSharesPriceValuePlanned Rule 10b5-1 plan: the insider set the trade up in advance, so its timing says less about their view. The box exists on Form 4 since April 2023. Filing
11 Sep 2026Ecolab ECLBuy3,690$276.64$1.0MNoForm 4filed 14 Sep 2026
6 Aug 2024West Pharmaceutical Services WSTSellafter exercising options30,732$304.71$9.4M10b5-1 planForm 4filed 8 Aug 2024
7 May 2024West Pharmaceutical Services WSTSellamended filing (4/A), not counted again; after exercising options66,000$366.65$24.2M10b5-1 planForm 4/Afiled 8 Aug 2024
7 May 2024West Pharmaceutical Services WSTSellafter exercising options66,000$366.65$24.2MNoForm 4filed 9 May 2024
27 Feb 2024West Pharmaceutical Services WSTSellafter exercising options64,132$359.85$23.1M10b5-1 planForm 4filed 29 Feb 2024
8 Aug 2023West Pharmaceutical Services WSTSellafter exercising options44,000$394.77$17.4M10b5-1 planForm 4filed 10 Aug 2023
9 May 2023West Pharmaceutical Services WSTSellafter exercising options44,000$363.11$16.0MNoForm 4filed 11 May 2023
7 Mar 2023West Pharmaceutical Services WSTSellafter exercising options44,000$322.35$14.2MNot statedForm 4filed 9 Mar 2023
5 Dec 2022West Pharmaceutical Services WSTSellafter exercising options44,000$238.99$10.5MNot statedForm 4filed 8 Dec 2022

From Form 4: open-market purchases (code P) and sales (code S) only; awards, option exercises, tax withholding and gifts are not counted. Greyed rows are amended copies or another filer's report of the same trade and count nowhere. Measures activity, not value. Not investment advice.